As previously reported, Exane BNP Paribas downgraded Accenture (ACN) to Neutral from Outperform with a $375 price target The firm sees a slower growth recovery Accenture after IBM and Capgemini cut their full year outlooks and suggested the first half of 2025 will likely remain challenging. While Accenture is better positioned than Capgemini to benefit from its scale in North America and exposure to sectors where a recovery is underway, it has high exposure to sectors which appear to still be weakening globally, such as manufacturing, the analyst tells investors in a research note. Shares of Accenture are down 4% to $349.21 in midday trading.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACN:
- Accenture downgraded to Neutral from Outperform at Exane BNP Paribas
- Accenture awarded $1.6B Air Force task order
- Accenture launches ‘Federal AI Solution Factory’ with Google Public Sector
- Accenture acquires supply chain consulting firm Joshua Tree Group
- Accenture’s AI Challenge: Balancing Innovation Risks with Maintaining Market Leadership